SCHEMBL20088445

SCHEMBL20088445

CNCCC(=O)NCc1cc(C)cc(C(F)(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TACR1 P25103 2/20 0.47
▸ MTOR P42345 2/20 0.44
▸ RHOC P08134 1/20 0.43
▸ RHOA P61586 1/20 0.43
▸ MLYCD O95822 1/20 0.43
▸ HDAC3 O15379 1/20 0.42
▸ HDAC1 Q13547 1/20 0.42
▸ HDAC2 Q92769 1/20 0.42
▸ HDAC10 Q969S8 1/20 0.42
▸ HDAC11 Q96DB2 1/20 0.42
▸ HDAC8 Q9BY41 1/20 0.42
▸ HDAC6 Q9UBN7 1/20 0.42
▸ MMP2 P08253 1/20 0.41
▸ MMP9 P14780 1/20 0.41
▸ MMP8 P22894 1/20 0.41
▸ MMP12 P39900 1/20 0.41
▸ MMP14 P50281 1/20 0.41
▸ P2RX1 P51575 1/20 0.40
▸ TMPRSS4 Q9NRS4 1/20 0.40
▸ NOS3 P29474 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15844339 0.93 TACR1 (0.53) TACR1MTORRHOCRHOAMLYCD
SCHEMBL20088441 0.86 TACR1 (0.50) TACR1MTORMLYCDHDAC3HDAC1
SCHEMBL20088438 0.83 TACR1 (0.49) TACR1MTORMLYCDP2RX1TMPRSS4
SCHEMBL17342648 0.78 TACR1 (0.56) TACR1MTORRHOCRHOAMLYCD
SCHEMBL25780517 0.77 MTOR (0.46) TACR1MTORMLYCDP2RX1TMPRSS4
SCHEMBL21565748 0.77 TACR1 (0.53) TACR1MTORMLYCD
SCHEMBL12765145 0.77 NOS1 (0.43) TACR1MTORRHOCRHOAMLYCD
SCHEMBL6645974 0.75 HPGD (0.57) TACR1MTORMLYCDHDAC3HDAC1
SCHEMBL11306116 0.75 TACR1 (0.63) TACR1MTORRHOCRHOAMLYCD
SCHEMBL15844152 0.75 TACR1 (0.59) TACR1MTORRHOCRHOAMLYCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180111894-A1 Benzimidazole Inhibitors of the Sodium Channel DeGiacomo, Mark G. (US) 2018-04-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180111894-A1 Benzimidazole Inhibitors of the Sodium Channel SCN1A, KCNJ11, KCNJ1 TACR1 1462/4885MTOR 2712/4885RHOC 3979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback